Egetis Therapeutics AB (publ) (OM: EGTX)
Health Care · Biotechnology · SE
Skr9.24
-6.95% today · +59.3% 1Y
Egetis Therapeutics AB (publ) (OM: EGTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $433.80M and employs 56 people.
Over the last twelve months the share price has gained 59.3%, trading between 3.63 and 10.14.
Tweenvest scores Egetis Therapeutics AB (publ) across four factors: quality 38/100, value 60/100, growth 100/100. Its strongest factor is growth.
EGTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $433.80M
- Revenue (TTM)
- $6.81M
- P/E
- —
- EPS
- -1.01
- Dividend yield
- —
- Beta (5Y)
- 0.78
- 52-week high
- Skr10.14
- 52-week low
- Skr3.63
- Avg volume (3M)
- —
- Shares outstanding
- 464.95M
- Employees
- 56
- Next earnings
- —
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
- ISIN
- SE0003815604
- Founded
- 2006
- Listed since
- Apr 7, 2011
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022 | $445.65M | CN¥5.76 | -7.10% |
| Guanhao Biotech Co.,Ltd.SZSE: 300238 | $442.97M | CN¥10.79 | -8.71% |
| Eupraxia Pharmaceuticals Inc.TSX: EPRX | $435.64M | CA$9.35 | -12.04% |
| Avacta Group PlcAIM: AVCT | $435.09M | £0.67 | +2.29% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $433.32M | $8.00 | -2.20% |
| Allogene Therapeutics, Inc.NasdaqGS: ALLO | $431.86M | $1.25 | -6.02% |
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $431.44M | $21.19 | +5.11% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $429.72M | NT$194.50 | -8.69% |
Figures last refreshed Oct 18, 2026.